Literature DB >> 6165947

Treatment of neovascular glaucoma with transscleral panretinal cryotherapy.

D R May, T J Bergstrom, A J Parmet, J G Schwartz.   

Abstract

Transscleral panretinal cryotherapy was used to treat six eyes with neovascular glaucoma. The media of each involved eye were sufficiently cloudy at the time of treatment to prevent adequate panretinal photocoagulation. A checkerboard pattern of eight 2.5-mm cryotherapy applications was placed in each quadrant. Five of the eyes were also treated with 180 degrees of cyclocryotherapy. Within 72 hours of treatment, the intraocular pressure in each eye returned to a controllable level. The iris neovascularization in each eye regressed or totally disappeared within six weeks.

Entities:  

Mesh:

Year:  1980        PMID: 6165947     DOI: 10.1016/s0161-6420(80)35122-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Evaluation of the blood-aqueous barrier by laser flare cell photometry following retinal cryocoagulation.

Authors:  Nicole Eter; Manfred Spitznas; Zaher Sbeity; Antje Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-05       Impact factor: 3.117

2.  Effect of partial cryoablation on retinopathy of prematurity.

Authors:  I Nissenkorn; R Axer-Siegel; I Kremer; I Ben-Sira
Journal:  Br J Ophthalmol       Date:  1991-03       Impact factor: 4.638

3.  Role of anterior retinal cryoablation in the management of neovascular glaucoma.

Authors:  S Sandramouli; R Sihota; N N Sood
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

4.  Panretinal cryotherapy in neovascular disease.

Authors:  S A Vernon; H Cheng
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

5.  Postvitrectomy hypotonia: the role of the vitreous and retinochoroidal lesions.

Authors:  H D Schubert; K Kuang; J Fischbarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-06       Impact factor: 3.117

6.  Rubeotic glaucoma.

Authors:  R J Smith
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.